O’Keefe Stevens Advisory: Baxter International ($BAX) Investment Case

In their Q1 2026 investor letter, O’Keefe Stevens Advisory initiates a new position in Baxter International ($BAX), purchasing shares in the high teens. The firm, which manages a concentrated long-only equity portfolio guided by valuation discipline, views Baxter as a classic trough-margin setup anchored by a management upgrade, a simplified business following a major divestiture, and what the firm believes is a compelling entry price that compensates for meaningful near-term operational risks.

Investment Highlight: Baxter International Inc. ($BAX)

Business Overview

• O’Keefe Stevens describes Baxter’s RemainCo as a focused hospital-products company generating approximately $11.2 billion in 2025 revenue across three segments: Medical Products & Therapies (IV solutions, infusion pumps, nutrition, and drug delivery, roughly half of sales); Healthcare Systems & Technologies (smart beds, patient monitoring, and Hillrom-era capital equipment); and Pharmaceuticals (injectable generics and compounding)
• The firm notes that Baxter completed the spin-off of its kidney care business as Vantive, closing the sale to Carlyle on January 31, 2025, for approximately $3.8 billion gross, leaving behind a streamlined hospital-products platform
• O’Keefe Stevens highlights that Baxter’s North Cove, North Carolina facility supplies approximately 60% of U.S. IV solutions and sustained damage from Hurricane Helene in late 2024, with production recovery continuing to weigh on margins into 2026

Operational Headwinds Creating the Opportunity

• The firm acknowledges that Baxter issued a voluntary recall of certain Novum IQ infusion pumps in 2025 due to potential safety and performance issues, with the FDA classifying them as Class I recalls; Reuters reported the recall was linked to 79 injuries and 2 deaths, with shipment holds in the U.S. and Canada expected to continue throughout 2026
• O’Keefe Stevens notes that the 2026 operating margin guide of 13–14% reflects the compounding of Hurricane Helene recovery costs, tariff absorption, and unfavorable product mix, which the firm believes are temporary factors depressing earnings well below normalized levels
• The firm also flags that fluid conservation practices adopted by hospitals during the Hurricane Helene disruption may have become embedded in clinical practice, potentially creating a more permanent reduction in IV solutions demand rather than a fully reversible cyclical headwind

Management Upgrade

• O’Keefe Stevens places significant weight on the arrival of new CEO Andrew Hider, who joined in September 2025 with a decade of experience at Danaher and most recently led ATS Corporation, where the firm notes revenue roughly doubled and shares more than tripled during his tenure from 2017 to 2024
• The firm characterizes Hider as a Danaher Business System operator and views his introduction of the Baxter Growth and Performance (GPS) operating framework as consistent with the lean-manufacturing, continuous-improvement playbook that has historically driven value creation in similar situations
• O’Keefe Stevens expects Hider to formalize a 100–200 basis point margin expansion roadmap at an investor day or capital markets event within the next 12 months
• The firm views the early dividend cut as appropriate and as removing a painful overhang rather than as a sign of fundamental distress

Valuation

• O’Keefe Stevens notes that Baxter trades near 11x forward earnings on what the firm believes are well below normalized earnings levels, with normalized operating margins closer to the high teens versus the current 13–14% guide
• The firm views the current valuation as compensating investors for the near-term risks, describing it as a price that requires only ordinary outcomes to generate acceptable returns
• O’Keefe Stevens frames the setup as archetypal for a three-to-five year holding period: a sub-scale medtech with a depressed multiple, a new operationally focused CEO, and portfolio simplification optionality

Risks

• O’Keefe Stevens identifies as the central bear case the possibility that Baxter’s asset portfolio is structurally weaker than the historical multiple implied, with the Novum IQ recall being the clearest example of competitive fragility
• The firm acknowledges that if IV solutions demand does not recover to prior levels, the hurricane-related disruption may have permanently pulled forward a behavioral change in hospital fluid management practices
• Leverage is flagged as an additional constraint, with the firm noting the balance sheet leaves limited room for error if the pump recall resolution drags, IV demand stays depressed, or Healthcare Systems & Technologies continues to underperform
• O’Keefe Stevens is candid that it is actively underwriting the risk that Baxter is not simply a trough-margin story but a company with weakened competitive positions

O’Keefe Stevens Advisory views Baxter International as a compelling trough-valuation opportunity anchored by a proven operational leader, a simplified post-divestiture business, and a near-11x forward earnings entry price that the firm believes more than accounts for the near-term headwinds from the Novum IQ recall, hurricane-related margin drag, and balance sheet constraints. The firm sees the Danaher-pedigree CEO introducing a structured operating system as the key catalyst for a multi-year margin recovery, and characterizes the current setup as the type of overlooked, fixable situation its process is designed to identify.

Click here for the full Pro Investor Letter.